Furthermore, there is evidence from experimental models of NAFLD on which it had been shown that TMAO increases the hepatic triglyceride accumulation by inhibition the farnesoid X receptor signalling.15 This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.